IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
IDEAYA Biosciences (NASDAQ: IDYA) announced the granting of inducement stock options to four newly hired employees on August 28, 2025. The Compensation Committee approved non-qualified stock options to purchase 139,800 shares of common stock under the company's 2023 Employment Inducement Incentive Award Plan.
The stock options have an exercise price of $24.93 per share, matching IDEAYA's closing price on the grant date. The options feature a 10-year term with a four-year vesting schedule: 25% vesting after one year and the remaining 75% vesting monthly over three years, contingent on continued employment.
IDEAYA Biosciences (NASDAQ: IDYA) ha comunicato la concessione di opzioni azionarie d'incentivo a quattro nuovi assunti in data 28 agosto 2025. Il Comitato per la Remunerazione ha approvato opzioni non qualificate per l'acquisto di 139.800 azioni di azioni ordinarie nell'ambito del piano aziendale 2023 Employment Inducement Incentive Award Plan.
Le opzioni hanno un prezzo di esercizio di $24,93 per azione, corrispondente al prezzo di chiusura di IDEAYA nella data di assegnazione. Hanno una durata di 10 anni e un piano di vesting quadriennale: il 25% matura dopo un anno e il restante 75% matura mensilmente nei successivi tre anni, subordinatamente alla continuazione del rapporto di lavoro.
IDEAYA Biosciences (NASDAQ: IDYA) anunci贸 la concesi贸n de opciones sobre acciones como incentivo a cuatro nuevos empleados el 28 de agosto de 2025. El Comit茅 de Compensaci贸n aprob贸 opciones no calificadas para comprar 139.800 acciones ordinarias conforme al plan de incentivos 2023 Employment Inducement Incentive Award Plan de la compa帽铆a.
Las opciones tienen un precio de ejercicio de $24.93 por acci贸n, igual al precio de cierre de IDEAYA en la fecha de concesi贸n. Cuentan con un plazo de 10 a帽os y un calendario de consolidaci贸n de cuatro a帽os: el 25% se consolida tras el primer a帽o y el 75% restante se consolida mensualmente durante los tres a帽os siguientes, condicionado a la continuidad en el empleo.
IDEAYA Biosciences (NASDAQ: IDYA)電� 2025雲� 8鞗� 28鞚检棎 雱� 氇呾潣 鞁犾瀰 毂勳毄鞛�鞐愱矊 鞙犾澑靹� 欤检嫕毵れ垬靹犿儩甓岇潉 攵�鞐枅雼り碃 氚滍憸頄堨姷雼堧嫟. 氤挫儊鞙勳洂須岆姅 須岇偓鞚� 2023 Employment Inducement Incentive Award Plan鞐� 霐半澕 氤错喌欤� 139,800欤�毳� 毵れ垬頃� 靾� 鞛堧姅 牍勳瀽瓴╉槙 欤检嫕毵れ垬靹犿儩甓岇潉 鞀轨澑頄堨姷雼堧嫟.
欤检嫕毵れ垬靹犿儩甓岇潣 頄夓偓臧�瓴╈潃 欤茧嫻 $24.93搿� 攵�鞐澕鞚� IDEAYA 膦呹皜鞕� 霃欖澕頃╇媹雼�. 靹犿儩甓岇潣 鞙犿毃旮瓣皠鞚� 10云�鞚措┌, 4雲� 氩犾姢韺� 鞀れ紑欷勳潉 霐半雼堧嫟: 1雲� 頉� 25%臧� 氩犾姢韸鸽悩瓿�, 雮橂ǜ歆� 75%電� 鞚错泟 3雲� 霃欖晥 毵れ洈 氩犾姢韺呺悩氅� 瓿勳啀 瓿犾毄 臁瓣贝鞚� 於╈”霅橃柎鞎� 頃╇媹雼�.
IDEAYA Biosciences (NASDAQ: IDYA) a annonc茅 l'attribution d'options d'incitation 脿 l'achat d'actions 脿 quatre nouveaux employ茅s le 28 ao没t 2025. Le comit茅 de r茅mun茅ration a approuv茅 des options non qualifi茅es pour l'achat de 139 800 actions ordinaires dans le cadre du plan 2023 Employment Inducement Incentive Award Plan de la soci茅t茅.
Le prix d'exercice est de 24,93 $ par action, correspondant au cours de cl么ture d'IDEAYA 脿 la date d'attribution. Les options ont une dur茅e de 10 ans et un calendrier d'acquisition sur quatre ans : 25 % sont acquis apr猫s un an et les 75 % restants s'acqui猫rent mensuellement sur les trois ann茅es suivantes, sous r茅serve de la continuit茅 de l'emploi.
IDEAYA Biosciences (NASDAQ: IDYA) gab am 28. August 2025 die Gew盲hrung von Incentive-Aktienoptionen an vier neu eingestellte Mitarbeiter bekannt. Der Verg眉tungsausschuss genehmigte nicht qualifizierte Aktienoptionen zum Erwerb von 139.800 Stammaktien im Rahmen des 2023 Employment Inducement Incentive Award Plan des Unternehmens.
Die Optionsaus眉bung erfolgt zu einem Aus眉bungspreis von $24,93 je Aktie, entsprechend dem Schlusskurs von IDEAYA am Gew盲hrungstag. Die Optionen haben eine Laufzeit von 10 Jahren und eine vierj盲hrige Vesting-Regelung: 25 % werden nach einem Jahr f盲llig, die restlichen 75 % werden 眉ber die folgenden drei Jahre monatlich vesting, vorausgesetzt die Besch盲ftigung bleibt bestehen.
- None.
- None.
The 2023 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of IDEAYA, or following a bona fide period of non-employment, as an inducement material to such individuals' entering into employment with IDEAYA, pursuant to Nasdaq Listing Rule 5635(c)(4).
The stock options have an exercise price of
About IDEAYA Biosciences
IDEAYA is a precision medicine oncology company committed to the discovery, development, and commercialization of transformative therapies for cancer. Our approach integrates expertise in small-molecule drug discovery, structural biology and bioinformatics with robust internal capabilities in identifying and validating translational biomarkers to develop tailored, potentially first-in-class targeted therapies aligned to the genetic drivers of disease. We have built a deep pipeline of product candidates focused on synthetic lethality and antibody-drug conjugates, or ADCs, for molecularly defined solid tumor indications. Our mission is to bring forth the next wave of precision oncology therapies that are more selective, more effective, and deeply personalized with the goal of altering the course of disease and improving clinical outcomes for patients with cancer.
Investor and Media Contact
IDEAYA Biosciences
Joshua Bleharski, Ph.D.
Chief Financial Officer聽
[email protected]
View original content to download multimedia:
SOURCE IDEAYA Biosciences, Inc.
FAQ
What is the exercise price of IDYA's new stock options granted on August 28, 2025?
How many shares of IDYA stock were granted in the inducement options?
What is the vesting schedule for IDEAYA Biosciences' August 2025 inducement stock options?
Why did IDEAYA Biosciences (IDYA) issue these stock options?
